Aktie A14QQF GRANULES INDIA LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Granules India Limited NSE India S.E.

Aktien

A14QQF

INE101D01020

GRANULES

Markt geschlossen - NSE India S.E.
Andere Börsenplätze
 13:43:48 02.05.2024 		% 5 Tage % 1. Jan.
424,6 INR +0,32 % Intraday Chart für Granules India Limited +2,45 % +4,74 %
30.04. Granules Pharmaceuticals Arm erhält US FDA-Zulassung für generisches Medikament gegen Gichtschübe MT
03.04. Granules India Unit erhält VAI-Status für Anlage in Virginia MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Granules India : ANDA Approval for Colchicine Capsules 0.6 mg
Granules Pharmaceuticals Arm Gets US FDA's Approval for Generic Drug for Gout Flares
Granules India Gets Zero Observation from US FDA After Inspection of Visakhapatnam, India Unit
Granules India Unit Gets VAI Status for Virginia Facility
Granules India Limited Announces Appointment of Directors
Granules India Limited Announces Cessation of Arun Rao Akinepally as Independent Director
Granules India Limited Announces Appointment of Sethu Madhavan Sankaran as Senior Vice President - Api Manufacturing & Operations
Granules India Limited Appoints Atul Dhavle as Chief Human Resources Officer
Granules India Limited Announces That J. Shravan Reddy Shall Cease to Be Senior Vice President & Head- API Manufacturing
Paracetamol maker Granules India posts marginal rise in Q3 profit
Granules India's Posts Gains in Fiscal Q3 Consolidated Net Profit
Granules India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Granules Pharmaceuticals Unit's Virginia Facility Gets Five Observations from US FDA
Granules India Gets US FDA Nod for Pantoprazole Sodium Delayed-Release Tablets
Granules India Limited Receives ANDA Approval for Pantoprazole Sodium Delayed-Release Tablets
Granules India Arm Gets US FDA Nod for Sildenafil for Oral Suspension
Paracetamol maker Granules India's Q2 revenue rises on higher N.America demand
Granules India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Granules India : Received ANDA Approval for Esomeprazole Magnesium Delayed-Release Capsules
Granules India Gets US FDA's Approval for Generic Drug for GERD Symptoms
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A14QQF Aktie
  4. A14QQF Aktie
  5. Nachrichten Granules India Limited
  6. Andere Sprachen